Daily Cardiology Research Analysis
Analyzed 105 papers and selected 3 impactful papers.
Summary
Three studies stood out today: a prespecified subgroup of the VESALIUS-CV randomized trial showed evolocumab prevents first major cardiovascular events in high-risk patients with diabetes but without known significant atherosclerosis; a network meta-analysis of 43 RCTs found IVUS- and OCT-guided PCI reduce MACE compared with angiography; and a phase 2 RCT (CADENCE) demonstrated sotatercept improves pulmonary vascular hemodynamics in CpcPH-HFpEF, an area with no proven therapies.
Research Themes
- Precision lipid-lowering for primary prevention in diabetes
- Imaging-guided PCI optimization and outcomes
- Activin signaling inhibition for pulmonary hypertension in HFpEF
Selected Articles
1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
In a prespecified VESALIUS-CV subgroup of 3655 high-risk patients with diabetes but without known significant atherosclerosis, evolocumab reduced first 3-point MACE (HR 0.69; absolute 5-year difference 2.1%) and 4-point MACE (HR 0.69; absolute difference 2.9%) versus placebo on top of statins. Median LDL-C at 48 weeks was 52 vs 111 mg/dL with evolocumab vs placebo.
Impact: Extends PCSK9 inhibitor benefits into primary prevention for high-risk diabetes without known significant atherosclerosis, suggesting earlier aggressive LDL-C lowering may prevent first events.
Clinical Implications: Consider evolocumab for selected high-risk patients with diabetes and elevated LDL-C despite statins, even without documented significant atherosclerosis, to prevent first MACE; shared decision-making should weigh cost, access, and absolute benefit.
Key Findings
- 3-point MACE over ~5 years: HR 0.69 (95% CI 0.52-0.91); absolute risk difference 2.1%.
- 4-point MACE: HR 0.69 (95% CI 0.55-0.86); absolute risk difference 2.9%.
- Median LDL-C at 48 weeks: 52 mg/dL (evolocumab) vs 111 mg/dL (placebo), P<.001.
- All-cause mortality was lower with evolocumab (HR 0.76; 95% CI 0.61-0.95).
Methodological Strengths
- Randomized, double-blind, placebo-controlled design across 774 sites in 33 countries.
- Prespecified subgroup with rigorous definition of ‘no known significant atherosclerosis’ and long median follow-up (4.8 years).
Limitations
- Findings are from a prespecified subgroup rather than the overall primary analysis.
- Generalizability beyond patients with diabetes and to cost-effectiveness in primary prevention requires further evaluation.
Future Directions: Pragmatic and cost-effectiveness studies to define thresholds for PCSK9i use in primary prevention among diabetics; biomarker- and imaging-guided selection for maximal absolute benefit.
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis. OBJECTIVE: To investigate whether evolocumab could prevent a first major cardiovascular event (MACE) in patients without known significant atherosclerosis. DESIGN, SETTING, AND PARTICIPANTS: VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab conducted across 774 sites in 33 countries and enrolling 12 257 patients with no prior myocardial infarction or stroke, LDL-C level 90 mg/dL or greater, and qualifying atherosclerosis or high-risk diabetes. This prespecified subgroup analysis examined outcomes in patients without known significant atherosclerosis (none of the following: prior arterial revascularization, arterial stenosis ≥50%, or coronary artery calcium score ≥100 Agatston units), all of whom had diabetes. Enrollment started in June 2019 and the last patient visit was July 2025, with a median follow-up of 4.8 years. INTERVENTION: Patients were randomized in a 1:1 ratio to subcutaneous administration of either evolocumab (140 mg every 2 weeks) or matching placebo added to optimally tolerated statin therapy. MAIN OUTCOMES AND MEASURES: The dual primary end points were composites of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE) and 3-P MACE plus ischemia-driven arterial revascularization (4-P MACE). Secondary end points included all-cause mortality. RESULTS: This predefined subgroup included 3655 patients (1849 in the evolocumab group and 1806 in the placebo group) with a median age of 65 years (57% female). Among those in the lipid substudy, the median LDL-C level at 48 weeks was 52 mg/dL in the evolocumab group vs 111 mg/dL in the placebo group (P < .001). A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group (hazard ratio [HR], 0.69 [95% CI, 0.52-0.91]; P = .009; between-group difference, 2.1% [95% CI, 0.4%-3.8%]). A 4-P MACE event occurred in 127 patients (5-year Kaplan-Meier estimate, 7.6%) in the evolocumab group compared with 178 patients (5-year Kaplan-Meier estimate, 10.5%) in the placebo group (HR, 0.69 [95% CI, 0.55-0.86]; P = .001; between-group difference, 2.9% [95% CI, 0.9%-4.9%]). There were 136 deaths (5-year Kaplan-Meier estimate, 7.8%) in the evolocumab group compared with 172 deaths (5-year Kaplan-Meier estimate, 10.1%) in the placebo group (HR, 0.76 [95% CI, 0.61-0.95]). CONCLUSIONS AND RELEVANCE: In high-risk patients without known significant atherosclerosis and with diabetes, evolocumab reduced the risk of a first major cardiovascular event. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03872401.
2. Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.
In the phase 2 CADENCE RCT (n=164), sotatercept reduced pulmonary vascular resistance at 24 weeks versus placebo in CpcPH-HFpEF, supporting activin signaling inhibition as a therapeutic strategy in a population with no proven treatments. Median PVR changes were −0.67 and −0.33 WU with sotatercept doses vs +0.26 WU with placebo.
Impact: First randomized evidence indicating that activin pathway inhibition can improve pulmonary vascular hemodynamics in CpcPH-HFpEF, a high-mortality phenotype lacking proven therapies.
Clinical Implications: If confirmed in phase 3, sotatercept could become a targeted therapy for CpcPH-HFpEF. For now, results support referral to specialized centers and trial enrollment; clinicians should monitor for evolving evidence.
Key Findings
- Primary endpoint met: greater reduction in pulmonary vascular resistance at 24 weeks versus placebo.
- Median PVR change: −0.67 WU (0.3 mg/kg), −0.33 WU (0.7 mg/kg) vs +0.26 WU (placebo).
- Baseline median PVR was 5.2 WU (IQR 4.0–6.9), confirming a clinically significant CpcPH-HFpEF phenotype.
Methodological Strengths
- Randomized, placebo-controlled, multicenter design with objective hemodynamic primary endpoint.
- Dose-ranging evaluation with standardized 24-week assessment interval.
Limitations
- Phase 2 sample size and 24-week duration limit power for clinical outcomes and long-term safety.
- Abstract reports truncated confidence intervals for shift estimates; full data needed for precise effect size interpretation.
Future Directions: Proceed to phase 3 trials powered for clinical outcomes (hospitalization, mortality) and define responder phenotypes, safety profile, and combination strategies with HF therapies.
BACKGROUND: Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction (CpcPH-HFpEF) involves remodeling in both the heart and pulmonary vasculature. Despite significant mortality, there are no proven therapies. METHODS: In this multicenter, randomized, placebo-controlled, phase 2 trial, adults received sotatercept (0.3 or 0.7 mg/kg) or placebo every 3 weeks. The primary end point was change in pulmonary vascular resistance at week 24. Hodges-Lehmann shift estimates described placebo-adjusted changes. RESULTS: 164 patients were randomized 54:55:55 to sotatercept 0.3 mg/kg, 0.7 mg/kg, and placebo, and baseline median pulmonary vascular resistance was 5.2 (interquartile range [IQR] 4.0-6.9) Wood units. The median change from baseline in pulmonary vascular resistance at week 24 was -0.67 Wood units in the sotatercept 0.3 mg/kg group, -0.33 Wood units in the sotatercept 0.7 mg/kg group, and 0.26 Wood units in the placebo group. The Hodges-Lehmann shift estimates in pulmonary vascular resistance were -1.02 Wood units (95% CI, -1.81 to -0.23; CONCLUSIONS: These findings provide proof of concept for improved pulmonary vascular and cardiac hemodynamics following activin signalling inhibition with sotatercept in patients with CpcPH-HFpEF.
3. Comparison of Intravascular Imaging-, Physiology-, or Angiography-Guided Approaches for Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.
Across 43 RCTs (39,291 patients), IVUS- and OCT/OFDI-guided PCI reduced MACE versus angiography guidance, and FFR was the only physiology approach with clear benefit. IVUS also outperformed iFR in network comparisons and showed benefit in both ACS and non-ACS presentations.
Impact: Synthesizes randomized evidence to support intravascular imaging-guided PCI over angiography, informing procedural strategy and potentially guideline updates.
Clinical Implications: When available, prefer IVUS or OCT guidance to reduce MACE; use FFR for lesion selection. These strategies may improve outcomes in both ACS and stable presentations.
Key Findings
- IVUS-guided PCI vs angiography: HR for MACE 0.69 (95% CI 0.60–0.79).
- OCT/OFDI-guided PCI vs angiography: HR 0.75 (95% CI 0.63–0.90).
- FFR-guided PCI vs angiography: HR 0.81 (95% CI 0.70–0.95); IVUS vs iFR: HR 0.74 (95% CI 0.55–1.00).
Methodological Strengths
- Network meta-analysis restricted to randomized controlled trials with frequentist random-effects modeling.
- Large sample size (39,291) with subgroup analyses by presentation and guidance objective.
Limitations
- Heterogeneity in trial designs, definitions of MACE, and operator expertise may influence estimates.
- Lack of individual patient data and potential transitivity violations inherent to network meta-analysis.
Future Directions: Head-to-head RCTs in complex lesions (left main, calcified, long lesions) and cost-effectiveness analyses to guide broad adoption; integration with AI-enabled imaging optimization.
BACKGROUND: Despite current guidelines recommending physiology- and intravascular imaging-guided percutaneous coronary intervention (PCI) in specific lesion subsets, angiography-guided PCI remains common in practice. The comparative effectiveness of these strategies remains uncertain. We aimed to compare clinical outcomes of PCI guided by intravascular imaging or physiological assessment versus conventional angiography. METHODS: We conducted a systematic review and network meta-analysis of randomized controlled trials, searching PubMed and EMBASE up to May 31, 2025. Eligible studies compared at least 2 of the following 6 guidance modalities in PCI: angiography, intravascular ultrasound (IVUS), optical coherence tomography/optical frequency domain imaging, fractional flow reserve, angiography-derived fractional flow reserve, and instantaneous wave-free ratio. The primary outcome was trial-defined major adverse cardiovascular events (MACEs). Hazard ratios (HRs) with 95% CIs were pooled using a frequentist random-effects network meta-analysis. Subgroup analyses assessed clinical presentation and guidance objectives such as decision making and procedural optimization. RESULTS: We identified 43 randomized controlled trials involving 39 291 patients. IVUS-guided PCI (HR, 0.69 [95% CI, 0.60-0.79]), optical coherence tomography/optical frequency domain imaging-guided PCI (HR, 0.75 [95% CI, 0.63-0.90]), and fractional flow reserve-guided PCI (HR, 0.81 [95% CI, 0.70-0.95]) were associated with a lower risk of MACEs compared with angiography-guided PCI. Furthermore, IVUS-guided PCI was associated with a lower risk of MACEs compared with instantaneous wave-free ratio-guided PCI (HR, 0.74 [95% CI, 0.55-1.00]). IVUS-guided PCI reduced the risk of MACE in both acute coronary syndrome and non-acute coronary syndrome patients. CONCLUSIONS: IVUS- and optical coherence tomography/optical frequency domain imaging-guided PCI were superior to angiography-guided PCI in reducing MACEs. Among the physiology-based approaches, only fractional flow reserve showed a clear benefit.